What does meropenem cover?
Meropenem is a broad-spectrum injectable antibiotic that is used to treat serious bacterial infections. It provides coverage against many Gram-negative and Gram-positive bacteria, and it is commonly used when clinicians want strong broad empiric coverage while culture results are pending.
Which bacteria does meropenem typically target?
Meropenem is often selected for infections where suspected or confirmed organisms include hard-to-treat Gram-negative pathogens. It is also active against several Gram-positive organisms. The exact “coverage list” depends on local resistance patterns and the specific infection syndrome (for example, intra-abdominal infection vs. hospital-acquired pneumonia).
Does meropenem cover Pseudomonas and other resistant Gram-negatives?
Meropenem is generally used in situations where clinicians need activity against difficult Gram-negative organisms, including Pseudomonas aeruginosa in many treatment guidelines and hospital protocols. Coverage against carbapenem-resistant organisms is limited; if resistance is present, meropenem may not work and alternative agents are needed.
Is meropenem active against MRSA and VRE?
Meropenem is not a go-to choice for MRSA (methicillin-resistant Staphylococcus aureus) or VRE (vancomycin-resistant Enterococcus). If MRSA or VRE is a likely cause, clinicians typically add or switch to agents with reliable activity against those organisms, based on susceptibility results.
Does meropenem cover anaerobes?
Meropenem can have activity against some anaerobic bacteria, which is one reason it may be used for infections like intra-abdominal infections. If anaerobic coverage needs to be broader or more specific, clinicians sometimes pair meropenem with additional anaerobic-active therapy depending on the suspected source and resistance patterns.
How is meropenem dosing and use decided for coverage?
Coverage is not just about the organism. Clinicians also factor in the infection site, severity, kidney function (dose adjustment may be needed), prior antibiotic exposure, and local antibiogram data. This determines whether meropenem is appropriate as monotherapy or should be combined with other antibiotics.
What happens if the suspected bacteria aren’t covered?
If the infection is caused by organisms that meropenem does not cover (for example, resistant strains like ESBL-producers with additional resistance mechanisms, carbapenem-resistant pathogens, MRSA, or VRE), treatment may fail. In that case, clinicians usually adjust therapy once cultures and susceptibility results return.
Meropenem vs other “broad-spectrum” choices
Meropenem is one option in the carbapenem class. Whether it is the best fit compared with alternatives (like other beta-lactams, piperacillin-tazobactam, cefepime, or ceftazidime-based regimens) depends on the suspected organisms, resistance rates, infection severity, and whether resistant Gram-negatives or anaerobes are priorities.
Sources
No sources were provided with your prompt, and none were allowed to be inferred. If you share where you’re using meropenem (e.g., pneumonia, UTI, intra-abdominal infection) and whether this is inpatient empiric therapy or culture-directed treatment, I can tailor the coverage explanation to that scenario.